Meitav Investment House’s Chemomab Therapeutics CMMB Stock Holding History

Meitav Investment House’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,756	Closed	-$129K	–	362
2022 Q2	$129K	Hold	8,756	–	–	﹤0.01%	327
2022 Q1	$167K	Sell	8,756 -636	-7%	-$12.5K	﹤0.01%	375
2021 Q4	$259K	Hold	9,392	–	–	﹤0.01%	357
2021 Q3	$416K	Sell	9,392 -774	-8%	-$47.1K	0.01%	327
2021 Q2	$773K	Buy	10,166 +8,088	+389%	+$790K	0.02%	266
2021 Q1	$239	Buy	+2,078	New	+$413K	0.01%	342
2020 Q4	–	Sell	-3,663	Closed	-$267K	–	418
2020 Q3	$267K	Sell	3,663 -2,035	-36%	-$138K	0.01%	347
2020 Q2	$500K	Buy	+5,698	New	+$387K	0.03%	223
2020 Q1	–	Sell	-5,813	Closed	-$521K	–	390
2019 Q4	$521K	Sell	5,813 -478	-8%	-$57.8K	0.04%	230
2019 Q3	$972K	Buy	6,291 +238	+4%	+$46.3K	0.07%	170
2019 Q2	$1.74M	Buy	6,053 +5,645	+1,384%	+$1.96M	0.12%	101
2019 Q1	$177K	Buy	+408	New	+$206K	0.01%	364

Other funds holding CMMB

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Meitav Investment House's CMMB Position: Q3 2022 in Review

Meitav Investment House sold out of Chemomab Therapeutics (CMMB) in Q3 2022, closing a stake of 8,756 shares — an estimated $129K sold.

Meitav Investment House first reported a position in CMMB in Q1 2019 and held it in 12 quarters. The position peaked at $1.74M in Q2 2019. 15 funds tracked by Wall St. Rank hold CMMB as of Q3 2022.

Meitav Investment House reported no remaining Chemomab Therapeutics position as of Q3 2022 after selling out during the quarter.
Meitav Investment House sold 8,756 Chemomab Therapeutics shares in Q3 2022, an estimated $129K.
Meitav Investment House first reported a position in Chemomab Therapeutics in Q1 2019 and held it in 12 quarters.
Meitav Investment House's Chemomab Therapeutics position peaked at $1.74M in Q2 2019.
15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2022.

Based on Meitav Investment House's 13F filing for Q3 2022, filed 31 Oct 2022.